Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche, Gen-Probe WNV Study Sites Begin Screening Under IND Approval

This article was originally published in The Gray Sheet

Executive Summary

FDA is consulting with the Office of the Chief Counsel regarding potential legal issues related to institutional review board approval of clinical trial sites participating in West Nile Virus IND studies

You may also be interested in...



JAMA Articles Assess Nucleic Acid West Nile Virus Screening Programs

Screening individual blood donations for West Nile Virus in high-prevalence regions using nucleic acid amplification test kits identifies low level infections missed by pooled sample testing, according to two studies in the Journal of the American Medical Association

JAMA Articles Assess Nucleic Acid West Nile Virus Screening Programs

Screening individual blood donations for West Nile Virus in high-prevalence regions using nucleic acid amplification test kits identifies low level infections missed by pooled sample testing, according to two studies in the Journal of the American Medical Association

West Nile Virus Assay Makers Race To Meet FDA’s Testing Needs By Summer

Focus Technologies expects to be the first company to offer a West Nile Virus clinical diagnostic in the U.S

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel